RxDoctor Payments Data

Santokh Walha, MD

Internal Medicine · Fort Myers, FLNPI 1164409561

Payments from drug & device makers

$5,294in general payments, 2019–2025

Across 127 payments — averaging $41.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Boston Scientific$253
  • Lilly USA, LLC$245
  • Pfizer$233
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$5,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,294 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$88,296
Medicare patients
237
Services billed
676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$79,254
XareltoRivaroxaban84$31,934
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,939
JardianceEmpagliflozin30$18,557
JanuviaSitagliptin Phosphate17$14,747
FarxigaDapagliflozin Propanediol12$13,120
MounjaroTirzepatide11$9,173
RexultiBrexpiprazole11$8,040
TrintellixVortioxetine Hydrobromide12$5,791
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen150$5,681
Gabapentin221$3,216
Atorvastatin Calcium265$2,887
Memantine Hcl57$2,845
Oxycodone Hcl135$2,809
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen119$2,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$233$79,254142 claims
Johnson & JohnsonXarelto$1,469$31,93484 claims
GSKTrelegy Ellipta$194$23,93934 claims
MerckJanuvia$16$14,74717 claims
AstraZenecaFarxiga$1,062$13,12012 claims
Lilly USA, LLCMounjaro, Olanzapine$245$10,24337 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$5,79112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →